SignalCorporate
UroGen Reports $68.0 Million of ZUSDURI Revenue and Provides Third Quarter 2026 Financial Results and Highlights
UroGen reports $68.0 million ZUSDURI revenue in Q3 2026 results.
Context
What happened: UroGen reported third quarter 2026 results, with ZUSDURI net product revenue of $68.0 million and FDA acceptance of the UGN-103 NDA for review.
Key numbers: ZUSDURI revenue $68.0 million, up 35% quarter over quarter. JELMYTO revenue $21.0 million versus $25.7 million in the third quarter of 2025.
Why it matters: Management cited growing repeat utilization and community adoption as support for the ZUSDURI commercial opportunity, while the UGN-103 NDA acceptance and new patent reinforce the company's stated view of long-term revenue potential in its bladder cancer portfolio.
Market: +0.1% today ($34.40), +51.5% YTD, 1.1x vol — as of 23:46 UTC
Coverage: 5 outlets in 24h
What changed
UroGen reported third quarter 2026 results, with ZUSDURI net product revenue of $68.0 million and FDA acceptance of the UGN-103 NDA for review.
Why it matters
Management cited growing repeat utilization and community adoption as support for the ZUSDURI commercial opportunity, while the UGN-103 NDA acceptance and new patent reinforce the company's stated view of long-term revenue potential in its bladder cancer portfolio.
Market: +0.1% today ($34.40), +51.5% YTD, 1.1x vol — as of 23:46 UTC